China becomes tenth country worldwide to award patent to LifeBond on its novel absorbable surgical adhesive biomaterials
LifeBond Ltd., a leading developer of absorbable biosurgical products for tissue repair, announced today that the State Intellectual Property Office of the People's Republic of China has granted the company its first Chinese patent. The patent, titled "Improved Cross-linked Compositions," relates to novel compositions of matter, which form the basis of LifeBond's unique surgical adhesive platform technology. This patent is applicable to LifeBond products in development, including LifeSeal™ Surgical Sealant and LifeMesh™ Self-fixating Hernia Mesh.
China joins the United States, Europe, Canada, Japan, Mexico, Israel, South Africa, Russia, and Australia in recognizing the novelty, inventiveness, and utility of LifeBond technology. The patents that have been granted to date are from two patent families, which form the broad foundation of LifeBond's intellectual property portfolio.
"LifeBond is at the forefront of a revolution to utilize biomaterial devices to integrate mechanical support with the body's natural tissue repair process," said Orahn Preiss-Bloom, the patent's primary inventor and co-founder of LifeBond. "We are excited that we have been able to translate our innovative technology into devices with great potential for patient benefit and look forward to continuing to grow our intellectual property portfolio in China, the US, Europe and around the world."
LifeBond has patent applications that include a total of nine patent families, with patents pending in more than fourteen countries.
LifeBond is represented in its intellectual property efforts by a highly experienced team of patent specialist offices, led by the offices of Graeser Associates International Inc and Dr. Dvorah Graeser Ltd. In addition, LifeBond’s patent portfolio and IP strategy has been reviewed in depth by members of some of the top US patent attorney firms.
The future of UK life sciences starts in the West Midlands